Business Wire

Empirix Announces Support for Traffic Analysis Across 5G Non-Stand-Alone Architectures

Share

Empirix Inc., a premier global provider of voice and data service assurance solutions, today announced the ability to monitor 5G user and control plane traffic in accordance with 3GPP Release 15 Non-Stand-Alone (NSA) Architecture options 3/3a/3x.

Entrusted to monitor and troubleshoot some of the world’s largest networks, Empirix’s service assurance platform, Diagnostix, formerly known as E-XMS, is capable of monitoring both hybrid and pure cloud-native 5G networks. This puts Empirix in a unique position to support communication service providers who have identified a migration path for their networks to 5G.

3GPP option 3x is emerging as the preferred choice for service providers who want to leverage previous-generation LTE networks. Largely based on the introduction of 5G Radio Access, this standard allows mobile providers to enhance both Quality of Service (QoS) and Quality of Experience (QoE) for their customers by integrating LTE core networks with non-standalone 5G radio systems. While appealing, this progressive approach creates blind spots and limits visibility across both core and cloud networks.

The Empirix Diagnostix solution provides operators with end-to-end visibility into traffic and network performance across 5G networks, legacy networks and services.

“We are very proud of the fact that our Diagnostix platform has become the industry standard for passive monitoring of fixed and mobile networks. We recognize the critical nature of service assurance for 5G network architectures and the latest release demonstrates our commitment to supporting this rapidly evolving market,” stated Franco Messori, Chief Strategy Officer at Empirix.

The newest version of Diagnostix, 6.2.3, can be deployed as either a physical, virtual or hybrid solution and is globally available today. Contact Empirix to learn more.

About Empirix

Empirix is the recognized leader in end-to-end network performance visibility with the unique ability to analyze customer behaviors by application in real time. We help service providers, mobile operators and enterprises optimize business processes to reduce operational costs, maximize customer retention and grow top-line revenue. Through monitoring, analytics and intelligence, Empirix helps companies around the world realize the full value of their technology investments.

Contact information

Jennifer Walsh
Manager, Global Marketing
978-313-7112
pr@empirix.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BIOCORP: Marketing Partnership on Mallya with iSage Rx in the Field of Digital Diabetes19.2.2020 20:00:00 EETPress release

Regulatory News: BIOCORP (Paris:ALCOR) (FR0012788065 - ALCOR / Eligible PEA PME), a French company specialized in the development and manufacturing of medical devices and smart drug delivery systems, today announced an alliance with US-based iSage Rx, LLC., a digital therapeutics company, focused on insulin dose optimization. In detail, the two companies are committed to integrating their respective technologies to simplify insulin dose capture and optimization. The integration of Mallya (a CE-marked connected device dedicated to insulin pens) into the iSage app (a clinically validated insulin titration platform cleared by the FDA) should enable patients with type 2 diabetes to simplify their insulin management. This will allow patients with diabetes to seamlessly capture, record, and store information about their insulin injections and while receiving automated guidance on how to adjust their insulin dose overtime ("titration"). Ryan Sysko, President and CEO of Amalgam Rx, Inc, said:

H.I.G. Capital Acquires Vernacare19.2.2020 19:28:00 EETPress release

H.I.G. Capital, a leading global alternative asset manager with over $35 billion of equity capital under management, announced today that one of its affiliates has acquired Vernacare Limited (“Vernacare”), a leading international healthcare products specialist. Terms of the transaction were not disclosed. Established in 1964, Vernacare is an industry-leading manufacturer of infection control systems. It has pioneered single-use toileting systems globally, offering patients hygienic care and provides healthcare institutions with efficient, cost effective and environmentally sound toileting and bathing solutions. With sales in over 60 countries, the business employs over 250 people across its UK headquarters in Chorley, its manufacturing plant in Bolton and its Canadian base in Toronto. James Mitchell, Principal at H.I.G. Capital, commented on the transaction: “Vernacare is a growing industry leader in the manufacture of products that contain and dispose of infectious waste – critical sy

250 Firms Select the Moody’s Analytics CreditLens™ Solution19.2.2020 18:55:00 EETPress release

Moody’s Analytics, a leading provider of financial intelligence, announced today that more than 250 institutions globally selected the CreditLens credit lifecycle management solution, less than a year after reaching the 100-client threshold. Built on the latest cloud-based technology, the CreditLens platform helps businesses digitally transform their commercial credit processes to make faster and better-informed decisions. It applies artificial intelligence and machine learning to facilitate process automation and help clients improve efficiency, reduce errors, and streamline workflows. The solution recently received a SOC 2 attestation report confirming its adherence to the American Institute of Certified Public Accountants’ security and availability controls standards. In 2019, Professional Bank became one of the first community banks in the US to automate its business loan applications. They accomplished this with the help of the CreditLens platform and other Moody’s Analytics tools

The Taulia Working Capital Summit Jets Into Johannesburg, Alongside Partners Greensill and Intellection19.2.2020 18:05:00 EETPress release

After two successful stints in San Francisco and Chicago, Taulia’s Working Capital Summit is set to launch in Johannesburg, South Africa for the very first time on March 11, 2020. The Working Capital Summit, hosted by The Money Show’s Bruce Whitfield will bring together some of the best and brightest minds in the financial technology business to discuss the latest in working capital finance solutions. The Working Capital Summit will provide a forum for key business minds to showcase their expert-leading industry knowledge, network with event-goers and discover unique ways to apply this knowledge to their own businesses. A recent Working Capital Index study conducted by JP Morgan found a staggering $460bn of working capital is confined across the supply chains of the S&P 1500 companies, which highlights an incredible opportunity for businesses to unlock trapped cash and propel their business’s growth through technology and innovation solutions. “Optimizing working capital and cash flow

Bioauxilium Introduces THUNDER™, a New Generation of TR‑FRET Cell Signaling Assay Kits19.2.2020 17:44:00 EETPress release

Bioauxilium Research Inc., a Canadian biotech specialized in the development and manufacturing of world-class time-resolved Förster resonance energy transfer (TR‑FRET) assay kits, announced today the launch of its proprietary no-wash THUNDER™ TR‑FRET cellular platform with the introduction of 68 new cell signaling assay kits. These top-quality, fully validated yet affordable cell-based kinase kits were designed to enable the simple, rapid and sensitive semi-quantitative detection of specific intracellular phosphorylated and/or total proteins in cell lysates. The ready-to-use THUNDER™ Cell Signaling Assay Kits are based on the higher specificity sandwich immunoassay format. However, in contrast to both conventional and improved ELISAs, they use a no-wash protocol with only one reagent addition and incubation step. This streamlined protocol dramatically decreases hands-on time and assay variability and is easily amenable to automation for high-throughput screening (HTS). The assays can b

RIBOMIC Announces First Injection in the Phase 2 Clinical Trial of RBM-007 (TOFU Study) in Subjects with Wet Age-Related Macular Degeneration19.2.2020 17:00:00 EETPress release

RIBOMIC, Inc., a clinical stage pharmaceutical company specializing in aptamer therapeutics and traded on the Mothers Market of the Tokyo Stock Exchange (Code Number: 4591), today announced that first patient has received injection in the phase 2 trial of RBM-007 for the treatment of exudative age-related macular degeneration (AMD) in the United States. The first site started enrollment at the end of December 2019 and five sites are now active across the United States. About RBM-007 and development background RBM-007 is a novel oligonucleotide-based aptamer with potent anti-FGF2 (fibroblast growth factor 2) activity. Currently approved therapies for wet AMD, intravitreal injections of anti-VEGF drugs, have shown dramatic visual benefits for wet AMD patients. However, a significant portion of wet AMD patients exhibit incomplete response to therapy, and over the extended management course can lose vision, with the formation of submacular fibrosis as one risk factor. RIBOMIC investigated

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom